Skip to main content
RT @KDAO2011: French study: 26 pts open label “After 6 days of treatment a combination of Hydroxychloroquine (200 mg tid) and azithromycin…

k dao KDAO2011

6 years 6 months ago
French study: 26 pts open label “After 6 days of treatment a combination of Hydroxychloroquine (200 mg tid) and azithromycin (z pack) significantly reduced SARS-CoV-2 viral load by PCR @rheumnow https://t.co/2Q6n3tcdW8
What advice can you give your patients during COVID mania? We cover the advice on NSAIDs, Plaquenil, JAK inhibitors, IL-6 inhibitors and TNF inhibito

Dr. John Cush RheumNow

6 years 6 months ago
What advice can you give your patients during COVID mania? We cover the advice on NSAIDs, Plaquenil, JAK inhibitors, IL-6 inhibitors and TNF inhibitors on RheumNow. Read here
There have been some rumblings of a Plaquenil (hydroxychloroquine) shortage; yet there is no shortage on the https://t.co/5EprIilu3p website. My pha

Dr. John Cush RheumNow

6 years 6 months ago
There have been some rumblings of a Plaquenil (hydroxychloroquine) shortage; yet there is no shortage on the https://t.co/5EprIilu3p website. My pharmacy says it is out and on backorder. Can anyone comment on a potential HCQ shortage? https://t.co/rLeiLbxeXL
Is COVID closing your clinic? Consider going remote. Dr. Kathryn Dao gives her spin on A Rheumatology Telemedicine in 6 Easy Steps. https://t.co/Bbpf

Dr. John Cush RheumNow

6 years 6 months ago
Is COVID closing your clinic? Consider going remote. Dr. Kathryn Dao gives her spin on A Rheumatology Telemedicine in 6 Easy Steps. https://t.co/BbpfVNg451 Also, tomorrow look for a video we will post with Dr. Alvin Wells talking about TELERHEUMATOLOGY - friday 3/20/20
NEJM Case Challenge: Which one of the following nonoperative management approaches is most appropriate for a 45-yoM who presents 3 days after an injur

Dr. John Cush RheumNow

6 years 6 months ago
NEJM Case Challenge: Which one of the following nonoperative management approaches is most appropriate for a 45-yoM who presents 3 days after an injury with clinical features of a trauma-induced minor meniscal tear and who has a pos. McMurray maneuver? https://t.co/QEQwxAYBt3
What advice can you give your patients during COVID mania? We cover the advice on NSAIDs, Plaquenil, JAK inhibitors, IL-6 inhibitors and TNF inhibito

Dr. John Cush RheumNow

6 years 6 months ago
What advice can you give your patients during COVID mania? We cover the advice on NSAIDs, Plaquenil, JAK inhibitors, IL-6 inhibitors and TNF inhibitors on RheumNow. Read here https://t.co/kM4OJ9wcbq
There have been some rumblings of a Plaquenil (hydroxychloroquine) shortage; yet there is no mention of shortage on the https://t.co/5EprIilu3p websit

Dr. John Cush RheumNow

6 years 6 months ago
There have been some rumblings of a Plaquenil (hydroxychloroquine) shortage; yet there is no mention of shortage on the https://t.co/5EprIilu3p website. My pharmacy says it is out and on backorder. Can anyone lend credence to a potential HCQ shortage? https://t.co/xWmGlLg9Tw
Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.
Ready for telemedicine/telerheumatology? Once you and your patient agree on a virtual visit, the following suggestions may help facilitate the interaction. If you have the ability and the capacity, record the visit.
As the highly virulent SARS-CoV-2 spreads over the world, uncertainty and fear for our patients with rheumatic diseases mount.  As of March 17, 2020 over 183,000* cases of Coronavirus disease 2019 (COVID-19) have been recorded, with the majority in China and Europe, but that may be the tip of the iceberg. Many more cases likely exist that are undetected due to shortages in testing supplies.   
We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus. This has led to a great deal of uncertainty by patients and providers about how rheumatic
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation

Dr. John Cush RheumNow

6 years 6 months ago
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA) https://t.co/FGVe6G10yM
Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.
×